31.03.2014 09:11:34
|
Forest Labs, Gedeon Richter Report Phase IIb Topline Results For Cariprazine
(RTTNews) - Forest Laboratories, Inc. (FRX) and Gedeon Richter Plc reported positive topline results from a Phase IIb study assessing the efficacy and safety of the investigational antipsychotic cariprazine in patients with bipolar depression.
Cariprazine, an investigational drug, is an orally active, potent dopamine D3-preferring D3/D2 receptor partial agonist atypical antipsychotic. It has a low affinity at other receptor sites such as 5-HT2C, muscarinic, and adrenergic receptor sites.
The trial included four treatment groups: cariprazine 0.75 mg/day, 1.5 mg/day, 3.0 mg/day, and placebo. Statistically significant improvements were observed in the cariprazine 1.5 mg/day group relative to placebo at 6 weeks for the primary endpoint, the Montgomery-Asberg Depression Rating Scale total score and the key secondary endpoint, the Clinical Global Impressions - Severity score.
This international, randomized, placebo-controlled, fixed-dose, 8-week Phase IIb trial evaluated the efficacy and safety of cariprazine in the treatment of patients with depressive episodes of bipolar I disorder.
Across all cariprazine doses, the most common adverse events were akathisia and insomnia.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Forest Laboratories Inc.mehr Nachrichten
Keine Nachrichten verfügbar. |